Novel selective inhibitor of the RUVBL1/2 complex demonstrates anticancer activity in vivo March 7, 2019
Santen launches two new research and development projects selected for the CiCLE program March 7, 2019
Phase III studies of triple combination of VX-445, tezacaftor and ivacaftor meet primary endpoint March 7, 2019
Sf3b1 gene mutation with Atm gene deletion yields new model of chronic lymphocytic leukemia March 7, 2019
Procarta Biosystems announces funding for development of new class of antibiotic precision medicines March 7, 2019
RSS